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Abstract
Objective: To evaluate the impact of diuretics and dopamine for both the prevention and treatment of renal
dysfunction in the acute care setting.
Study identification and selection: Studies were identified via MEDLINE, and through bibliographies of primary
and review articles. Articles were then screened by the author for studies addressing the use of diuretics or
dopamine in the prevention and/or treatment of renal dysfunction.
Data abstraction and literature appraisal: From individual studies, data were abstracted regarding design
features, population, intervention and outcomes. Studies were graded by levels according to their design.
Results: A total of 10 studies using diuretics and 30 involving dopamine were identified. Level I evidence exists
against the use of diuretics for radiocontrast-induced acute tubular necrosis, and loop diuretics given after vascular
surgery. There is level II evidence that diuretics do not improve outcome in patients with established acute renal
failure. Level II evidence also exists against the use of dopamine in the prevention of acute tubular necrosis in
multiple subsets of patients.
Conclusions: Routine use of diuretics or dopamine for the prevention of acute renal failure cannot be justified on
the basis of available evidence.
Introduction
The term acute renal failure (ARF) has been used to
encompass a wide variety of clinical disorders ranging
from glomerulonephritis to prerenal azotemia. It is gen-
erally defined as a rapid decline (within hours to weeks)
in glomerular filtration rate (GFR) and retention of
nitrogenous waste products. Each underlying disorder
has its own unique pathophysiology and separate set of
etiologies. Furthermore, many of these clinical syn-
dromes have specific treatments. Accordingly, it is not
possible to consider the issue of whether diuretics or
dopamine are useful in ARF without first considering
the differences between these individual disorders.
Moreover, data drawn from animal experiments, where
compounds such as uranyl nitrate or glycerol were used
to induce ARF, must be interpreted with caution [1].
Still, much of our understanding of these disorders, and
the effects of various treatments, comes from these
models. In general, diuretics and/or dopamine are
usually considered for the prevention or treatment of
acute tubular necrosis (ATN). The basic rationale is that
ischemic ATN should be improved by increasing renal
blood flow and that tubular obstruction should be
decreased by maintaining urine flow.
The use of diuretics to prevent or even ‘treat’ renal
dysfunction has become a widely accepted clinical prac-
tice. Indeed, management protocols for some routine
patients often include orders for furosemide when urine
output falls below some cutoff value. Some protocols
even utilize socalled ‘renal-dose’ dopamine in these cir-
cumstances. It is therefore necessary to review the evi-
dence in support of such practices. Given the broad
range of conditions predisposing to ARF and the multi-
ple comorbidities of critically ill patients, a systematic
review addressing the effect of different treatments must
be interpreted in light of these clinical features. University of Pittsburgh Medical Center, Division of Critical Care Medicine,
200 Lothrop Street, Pittsburgh, PA 15213-2582, USA
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© 1997 Current SCience LtdTherefore, the purpose of this review was to evaluate
the impact of diuretics and dopamine for both the pre-
vention and treatment of renal dysfunction in the acute
care setting.
Methods
Search strategy
A MEDLINE search was conducted using databases
from 1966 to May 1997. Articles dealing with kidney
(drug effects) and diuretics or dopamine were searched.
This pool of articles was then limited to English lan-
guage clinical trials or meta-analyses of human studies.
Bibliographies of review articles on these topics were
also searched by hand for additional studies meeting the
above criteria. This group of articles was then screened
by the author for studies addressing the use of diuretics
or dopamine in the prevention and/or treatment of ARF.
Inclusion and exclusion criteria
For the purpose of this review only loop diuretics, man-
nitol and dopamine were included. Loop diuretics
included the agents furosemide, bumetanide and torse-
mide. These agents have become the most widely used
for the indications considered in this review. Although
ethacrynic acid is also a loop diuretic, it was excluded
because it is not commonly used in clinical practice.
Additionally, other diuretic agents such as thiazides
were excluded. Similarly, this review will not discuss any
of the yet experimental agents such as atrial natriuretic
factor. The primary analysis included only studies that
involved humans and were published in English.
Critical appraisal methods
Individual studies were graded by levels according to the
criteria in Table 1, adapted from Cook et al [2]. When
multiple studies were available, the highest level study
was used. Clinical trials of the effectiveness of diuretics
or dopamine were judged to be effective only if the out-
come measures were of clinical significance (eg mortal-
ity, need for hemodialysis) or in terms of biochemical
evidence of organ function (serum creatinine or creati-
nine clearance) following the maneuver. Surrogate mar-
kers such as urine output or renal blood flow were not
considered as evidence of effectiveness. Furthermore,
trials of dopamine were not considered controlled unless
confounding variables such as blood pressure and car-
diac output were reported. Similarly, for both diuretics
and dopamine, the volume status of the control and
treatment groups must have been similar.
Results
The literature search results are shown in Table 2.
Seven diuretics studies were located via MEDLINE and
another three from review article bibliographies [3-12].
For dopamine these numbers were 13 and 17, respec-
tively [13-42]. The results of the critical appraisal are
s h o w ni nT a b l e s3 –4. Studies evaluating the effective-
ness of these agents in ATN were divided into three
clinical scenarios:
1. prevention of radiocontrast-induced ATN;
2. prevention of ischemic ATN, and
3. treatment of established ATN.
Radiocontrastinduced ATN
Radiocontrast-induced ATN is rare in patients without
underlying renal, cardiac or hepatic dysfunction and
occurs most commonly in patients with diabetic nephro-
pathy [43]. In this group the incidence approaches 50%,
depending on the degree of baseline renal function and
the use of ionic vs nonionic contrast media [44]. Several
forms of therapy have been proposed to prevent or treat
radiocontrast-induced ATN, including saline, furose-
mide, mannitol, calcium channel blockers, dopamine,
atrial natriuretic peptide and theophylline [44]. There
are no placebo controlled trials testing the effectiveness
of any of these therapies. Virtually all studies have used
hydration (usually with 0.45% saline) in addition to the
agent being tested and most authors recommend its use.
However, even then, little comparative data exist for
these potential treatments. One exception is the study
Table 1 Levels of evidence for treatment effect
Level I Randomized trials with low false positive (a) and low false
negative (b) error (ie high power)
Level II Randomized trials with high a error or low power
Level III Non-randomized concurrent cohort studies
Level IV Non-randomized historic cohort studies
Level V Case series
Adapted from Cook et al [2].
Table 2 Literature search results
Diuretics Dopamine
Total number of trials 10 30
Number fulfilling outcomes criteria 8 20
Radiocontrast ATN 2 2
Prevention of ischemic ATN 5 16
Treatment of ATN 3 12
ATN = acute tubular necrosis.
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osemide plus saline, mannitol plus saline and saline
alone; again, 0.45% saline was used. This randomized
trial of 78 ‘high-risk’ patients found that both diuretic
regimens were less effective in preventing ATN than sal-
ine alone (relative risk of ATN using mannitol 2.5 or
furosemide 3.6 vs saline alone; P = 0.02). Another study,
by Weinstein et al, found that renal function
significantly deteriorated in patients pretreated with fur-
osemide [4].
As shown in Table 1, to date only two clinical trials
have been published using dopamine to prevent radio-
contrastinduced ATN. Hall et al [28] studied the effects
of dopamine infusion on serum creatinine assessed at
day 3 after radiocontrast administration in patients with
baseline serum creatinine levels of > 2.0 mg/dl. This
level III study did show an improvement in serum crea-
tinine with dopamine compared to a control group
which received mannitol. However, given the evidence
that mannitol may actually be harmful in this setting
[3], this was probably not the appropriate control group.
In the only other controlled trial, Weisberg et al [24]
found no difference in the incidence of ATN with or
without dopamine (30–40%) in a small series of patients
(n = 30). Thus, for this indication we can safely con-
clude that diuretics and dopamine are clearly not helpful
and may even be harmful, while volume expansion with
0.45% saline is unproven but potentially beneficial.
Prevention of ischemic ATN
Of the five studies listed in Table 1, only one trial used
loop diuretics. Hager et al [8] randomized 121 patients
to receive either furosemide (1 mg/h) or placebo starting
immediately after major thoraco-abdominal or vascular
surgery and continuing throughout the intensive care
unit (ICU) stay. The authors measured creatinine clear-
ance and found no difference between furosemide and
placebo. Unfortunately, the study was unable to address
the use of loop diuretics given during the procedure.
The facts are even less clear regarding mannitol in
vascular surgery. The only controlled study available is
by Beall et al from 1963 [5]. This study compared the
outcomes of 30 patients who underwent elective abdom-
inal aortic aneurysm repair. Patients were randomized to
receive either no pre-operative fluid, iv hydration only
or iv hydration plus mannitol as required to keep urine
output > 60 ml/min. There was no change in renal
function or postoperative urine output between the lat-
ter two groups. Although this negative study was cer-
tainly underpowered, it remains the only controlled trial
of mannitol in vascular surgery to date. The following
year, Powers et al reported the outcomes of 104 patients
treated with mannitol [6]. This uncontrolled study
reported that all patients had an increase in urine out-
put and none developed ATN. No recent studies have
been carried out to address this issue and it is unlikely
that any will. In other types of surgery, such as coronary
artery bypass [9] or biliary surgery [10], small studies
have also been unable to demonstrate a benefit asso-
ciated with mannitol. Given these considerations, and in
the absence of clinical data, diuretics cannot be recom-
mended to prevent ATN.
Table 3 Evidence for loop diuretic therapy in acute
tubular necrosis (ATN)
Indication (result) Strength of Source
evidence
Radiocontrast ATN
For prevention (no) Level I Solomon et al [3]
Ischemic ATN
For prevention (?) No data in humans
Vascular surgery (no) Level I
* Hager et al [8]
Treatment of ATN
Rhabdomyolysis (no) Level IV Better et al [7]
Improves outcome (no) Level II Kleinknecht et al [11]
*Loop diuretics were begun after surgery and continued through the ICU stay.
Table 4 Evidence for low-dose dopamine therapy in
acute tubular necrosis (ATN)
Indication (result) Strength of
evidence
Source
Prevention of ATN
Critically ill/sepsis (no) Level II Lherm et al [14]
Cardiothoracic/
vascular surgery (no) Level II Myles et al [23]
Liver transplantation
(no)
Level II Swygert et al [30]
Renal transplantation
(no)
Level II Grundman et al
[39]
Treatment of ATN
Critically ill/sepsis (?) No data available
in humans
Surgery (no) Level V Flancbaum et al
[13]
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lished to date, both for prevention of ATN and treat-
ment of early ATN (including radiocontrast-induced
ATN). However, only 20 of these used outcomes other
than surrogate markers (eg urine output, renal blood
flow), and only three were positive. These included the
study by Hall et al [28], cited above, and two others
which were both methodologically inferior, one level IV
and one level V. Polson et al [38] found a significant
difference in creatinine clearance and a decrease in ARF
in liver transplant patients treated with 2 μg/kg/min
dopamine. The findings of this level IV study were not
s u p p o r t e db yal e v e lI Is t u d yf r o mS w y g e r tet al [30],
also in liver transplant patients. The Swygert study used
3 μg/kg/min dopamine and found no difference com-
pared to placebo in terms of creatinine clearance or
incidence of ARF (4% in both groups). The results of a
small level V study by Palmieri et al [26] appear to sug-
gest that dopamine may be useful in shortening the
recovery time from interleukin-2-induced ARF. Apart
from these two studies, the remaining 17
[13-25,27,29-37,39-42], collectively enrolling over 700
patients, are all negative. Among these is a recent level
II study by Lherm et al [14] in which dopamine infusion
failed to improve renal function in patients with sepsis
except for transiently increasing creatinine clearance in
patients without shock.
Treatment of established ATN
Of the three trials evaluating the use of diuretics in the
treatment of ATN, two fulfilled outcome criteria. Both
studies evaluated the effects of treatment on mortality
and the need for dialysis. In the first, Kleinknecht et al
[11] randomized 66 patients to receive furosemide or
placebo. Although, the furosemide group did experience
improved urine output, there were no significant differ-
ences between the two groups in terms of renal recov-
ery, days on dialysis or mortality. A second study by
Brown et al [12] had similar results. In this study, 58
patients were given a single dose of furosemide (1 g)
and then randomized either to receive or not receive
continued diuretic therapy; again, there were no differ-
ences between the two groups in terms of need for dia-
lysis or survival. Unfortunately, even the two studies
together lack sufficient power to entirely rule out the
possibility that diuretics have a beneficial effect on survi-
val. Nonetheless, the available literature to date does not
support a survival benefit for this therapy.
Discussion
The idea that the emperor indeed ‘has no clothes’ may
be difficult for some clinicians to accept. The use of
diuretics and low-dose dopamine to prevent or treat
renal dysfunction in the operating room or ICU has
become routine in many centers. One might ask how
this all came to be in the first place; are there not sound
theoretical grounds on which to build a case for these
interventions? Is it not likely that all or most of these
studies are sufficiently under-powered to have missed a
clinically significant effect? Indeed, Tables 3 and 4 con-
tain very few level I studies. However, on closer scrutiny
the theoretical grounds which form the basis for these
therapies are beginning to give way under the weight of
some new experimental evidence.
Diuretics and ATN
Experimentally, the effectiveness of diuretics in the pre-
vention of ischemic ATN appears to be related to tim-
ing. While no data exist in humans, several lines of
evidence from animal experiments suggest that interven-
tions such as diuretics may be useful if given within
minutes (or perhaps the first few hours) following a
renal insult [1]. Once this time limit has passed, the
intervention will be ineffective. This is because the uni-
fying principle is cytoprotection of the renal tubular
cells which, if lethally injured, may only be ‘rescued’ for
a short time. The injury to the renal tubular cells has
been attributed to four major factors: renal vasoconstric-
tion, reduction of glomerular capillary permeability, tub-
ular obstruction and transepithelial back-leak of filtrate
[45]. In theory, loop diuretics may be useful in combat-
ing each of these factors. These agents decrease the
metabolic demand of the renal tubular cell, reducing its
oxygen requirement and hence increasing its resistance
to ischemia [46] and perhaps to other toxic insults as
well. A greater urine flow may also reduce the incidence
of tubular obstruction and the higher hydraulic pres-
sures may reduce the back-leak of filtrate [47]. In the
latter case, fluid resuscitation alone may produce much
of the same effect [7].
In practical terms these data from animal studies offer
little to guide practice in the care of patients, though
they provide great insight into the various mechanisms
of ATN. This is because it is not usually possible to
anticipate the renal injury and act within the time
required to have an effect. However, there are notable
exceptions, such as aortic cross-clamping in aneurysm
repair. The use of loop diuretics has become routine for
this indication in many institutions. Nonetheless there
appears to be no evidence in support of this approach.
Additionally, there are some situations in which the
renal injury is subacute or mild and sustained. Such is
often the case in conditions such as rhabdomyolysis,
drug-induced renal injury, hepatorenal syndrome, and
ARF associated with cardiopulmonary bypass circulation
in cardiac surgery (especially in patients with pre-opera-
tive renal impairment [48]). In these conditions it is
often possible to act in an attempt to prevent or reduce
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renal injury vary somewhat between these forms of ‘sub-
acute’ renal failure, all are exacerbated by hypovolemia
and, therefore, any consideration of the use of loop
d i u r e t i c sm u s ti n c l u d eap r o v i s i o nf o ra d e q u a t ev o l u m e
replacement. This requirement makes it difficult to
separate the effects of diuretics from the effects of the
increased fluid given to prevent diuretic-induced hypo-
volemia. Dramatic evidence exists from a case-controlled
study to support the use of (‘early and aggressive’)
hydration along with forced alkaline/osmotic diuresis
(mannitol) for the treatment of ATN secondary to trau-
matic rhabdomyolysis [7]. In this study, delayed treat-
ment in a series of seven patients was associated with a
100% incidence of ARF, while in another seven patients
prompt treatment was 100% successful in avoiding this
complication even though renal injury had already
begun. Unlike loop diuretics, mannitol functions as an
intravascular volume expander, at least initially, and may
also function as a free-radical scavenger. None of these
patients received loop diuretics and, indeed, the authors
have argued that hydration alone may have been suffi-
cient to produce many of salutary effects of the osmotic
diuresis [7].
Once ATN is established there are no therapies that
have been proven to reverse it. The most a clinician can
do is to manage the complications of ARF and limit
further renal insult so as to assure the best chance of
renal recovery. Diuretics can be both useful and harmful
in this regard. The harm comes from reducing the cir-
culating volume too much and adding a prerenal insult
on top of the established ATN. The recovering kidney
m a yb ee v e nm o r es u s c e p t i b l et ot h i s‘second hit’ and
m a yb ep r o f o u n d l yi n j u r e db yar e l a t i v e l ym i l dd e c r e a s e
in perfusion, especially with the pre-existing renal dis-
ease. Clinicians may inadvertently produce this injury if
diuretics are dosed according to the amount of periph-
eral edema or body weight without consideration of
intravascular volume. This may be of particular concern
in many critically ill patients with hypoalbuminemia.
These patients may have coexisting total body volume
overload and intravascular volume depletion.
However, if volume status is monitored closely, diure-
tics can be useful in the conversion to nonoliguria. This
goal may be reasonable in certain situations and patients
are clearly easier to manage without volume overload
and electrolyte imbalances. In this regard, loop diuretics
appear to be more effective and less toxic when given as
a continuous infusion rather than as a bolus. In a rando-
mized, crossover trial, Rudy et al [49] evaluated the
effectiveness of continuous infusion vs bolus dosing of
bumetanide. Continuous infusion produced 48 mmol
more net sodium excretion (95% CI 16–80 mmol, P =
0.01), and less toxicity. It is also important to note that
large bolus doses of loop diuretics may cause transient
renal vasoconstriction. Despite these potentially useful
effects of diuretic therapy, there is no evidence that con-
verting oliguria into nonoliguria is effective in reducing
mortality or the need for dialysis. As detailed above, this
question has now been evaluated in two randomized
trials [11,12].
Medullary ischemia, renal blood flow and dopamine
In general, ATN occurs more commonly in patients
with certain types of underlying physiologic states or
diseases (elderly, relative hypovolemia, diabetes, underly-
ing kidney disease, heart disease, hepatic cirrhosis, cer-
tain autoimmune diseases and malignancies) as well as
in certain clinical settings (sepsis, surgery, trauma, drug-
induced). Indeed, one of the most commonly anticipated
etiologies of ATN is the use of iv contrast agents for
imaging studies [43]. Although the pathogenesis of renal
injury secondary to radiocontrast agents is not entirely
understood, it appears to be due to medullary ischemia
[3,50]. For some time, it has been postulated that this
ischemic injury occurs on the basis of decreased renal
blood flow secondary to renal vasoconstriction. It is
therefore surprising that studies have now shown that
renal blood flow actually increases with radiocontrast
[24]. This has led some investigators to hypothesize that
medullary ischemia is a demand-side phenomenon. In
other words, the ionic load leads to medullary ischemia
because the medullary cellular oxygen demand becomes
greater than the supply [51,52]. This aspect of renal
physiology also has implications for the use of agents
like dopamine.
Like loop diuretics, dopamine is frequently used by
clinicians to increase urine output in ARF in the hope
that such a maneuver might attenuate renal injury or
improve survival. Much of the enthusiasm for this agent
comes from the belief that dopamine increases renal
blood flow and that such an outcome is in fact desirable.
Additionally, clinicians often interpret an increase in
urine output as proof that these two assumptions are
valid. Indeed, dopamine may increase urine output
through four separate mechanisms. Dopamine stimu-
lates both dopaminergic and adrenergic (both alpha and
beta) receptors. As such, dopamine may affect renal
blood flow by direct vasodilatation (dopamine recep-
tors), by increasing cardiac output (beta receptors) or by
increasing perfusion pressure (alpha receptors). At lower
doses, particularly less than 2 μg/kg/min, the dopami-
nergic effects tend to predominate, although wide varia-
bility appears to exist across patients and clinical
conditions. In the appropriate clinical setting, any of
these mechanisms might increase effective renal plasma
flow and thus increase urine output. Under such condi-
tions, the increase in urine output might well be
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mine may increase urine output by yet a fourth mechan-
ism, that of inhibition of sodium-potassium ATPase at
the tubular epithelial cell level [53]. The effect of this
final mechanism is to increase sodium excretion and
thereby diuresis. Thus, apart from its direct and indirect
effects on the renal vasculature, dopamine increases
urine output because it is a diuretic.
The natriuretic/diuretic effects of dopamine are of
importance not only because they may lull clinicians
into believing that they are improving renal function
when they observe an increase in urine output with the
drug, but also because this increase in urine output may
come with unexpected effects. Most ‘enthusiasts’ use so-
called ‘renal-dose dopamine’ in the belief that they can
improve renal blood flow and that this will restore oxy-
gen delivery to portions of the kidney that are dysoxic.
Unfortunately, as already discussed, the problem may
not be remedied simply by increasing total renal blood
flow. This is because the area of the kidney that is most
at risk from ischemia is the very area least likely to ben-
efit from dopamine infusion. This area is the outer
medulla. Normally, outer medullary cells live on the
edge of dysoxia. Oxygen diffuses from the descending to
ascending vasa recta within the vascular bundles limiting
oxygen delivery to the renal medulla [52]. In addition
the medulla suffers from unusually high oxygen demand
related to tubular transport activity (medullary oxygen
extraction approaches 90% [54]. Thus, the renal medulla
is constantly on the brink of dysoxia owing to high
demand and low delivery of oxygen.
Given these considerations, it is certainly understand-
able for clinicians to desire to increase renal blood flow
in the hope of improving medullary oxygen delivery.
However, Heyman et al have recently demonstrated that
although dopamine increased outer medullary blood
flow in the hypovolemic rat, it failed to improve outer
medullary dysoxia [55]. In fact, analogous to the situa-
tion with radio-contrast, the increase in solute delivery
to the distal tubular cells produced by the natriuretic
effects of dopamine (via inhibition of proximal tubular
reabsorption) might actually increase their oxygen con-
sumption and therefore increase rather than decrease
the risk of ischemia [56].
With these ‘myths’ of experimental evidence dis-
pelled, or at least severely questioned, it is not surpris-
ing that clinical trials have failed to demonstrate a
beneficial effect from dopamine infusion in the setting
of treatment or prevention of ATN [57,58]. Data of
this sort also call into question the appropriateness of
increasing urine output in the first place. As we have
seen with other types of diuretics, converting oliguric
to nonoliguric renal failure may provide certain man-
agement advantages, but does not affect overall renal
recovery or outcome. Accordingly, on the basis of
existing evidence, the use of dopamine to improve
renal function cannot be recommended. This is not to
say that dopamine is not a useful drug. Indeed, dopa-
mine’s multiple effects (even at low doses) make it the
perfect pressor/inotropic agent when such a combina-
tion is warranted. It is a common clinical scenario in
which a patient is both modestly hypotensive/vasodi-
lated and has a degree of cardiac dysfunction. Such a
patient may well benefit from the combined inotropic,
vasopressor, renal vasodilator and diuretic effects of
this drug. However, as always, when safer or less inva-
sive alternatives are available, they should be used first.
For example, loop diuretics are much more effective
diuretics than dopamine and are much safer. Similarly,
dobutamine would be a better alternative for the
patient who primarily requires an inotrope, and nore-
pinephrine would be a better choice for a vasodilated,
hyperdynamic patient.
Certainly, dopamine has a number of potential disad-
vantages. In a recent study, Segal et al demonstrated
that low-dose dopamine caused earlier onset of gut
ischemia [59]. Even at low doses, dopamine may
increase cardiac contractility and systemic resistance,
and can cause tissue necrosis and digital gangrene [60].
Furthermore, even if dopamine were without risk, its
effects can be unpredictable. This point was stressed by
Flancbaum et al, who demonstrated that low-dose infu-
sion alone produces a drug-dependent increase in the
urinary output in oliguric, euvolemic ICU patients, and
that the maximal effect is temporally variable [13].
Given the fact that the renal effects of low-dose dopa-
mine in patients with sepsis syndrome decrease with
time, it has been suggested that there is a desensitization
of renal dopaminergic receptors [14]. The above consid-
erations argue against the routine use of ‘renal-dose
dopamine’ for patients with renal insufficiency.
Conclusions
The use of diuretics in the management of ARF remains
controversial despite several advances in the under-
standing of the pathogenesis of renal failure and the
mechanisms of action of the agents commonly used to
manage it.
At the present time the limited observational and
experimental evidence available moderately supports the
following guidelines:
1. For prophylaxsis against radiocontrast-induced
ATN, saline infusion should be administered for optimal
hydration; neither diuretics nor dopamine appear effec-
tive and may be harmful.
2. For the prevention of ischemic ATN, although ani-
mal data suggest this intervention would be helpful,
there are no human data to support the use of diuretics.
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stantiated to improve outcome in human studies and
may prove to be deleterious in certain clinical settings.
4. In the management of rhabdomyolysis, loop diure-
tics should probably be avoided, although mannitol may
be effective on the basis of level IV evidence.
5. When loop diuretics are used in the management of
ARF, continuous infusion may be more efficacious than
bolus administration in achieving diuresis. However,
there is no evidence that this maneuver improves survi-
val or renal recovery.
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